言語:
日文
English
簡体中文
繁體中文
ヘルプ
ログイン
ホームページ
スイッチ:
ラベル
|
MARC形式
|
国際標準書誌記述(ISBD)
Dyslipidemias[electronic resource] :...
Dyslipidemias[electronic resource] :pathophysiology, evaluation and management /
レコード種別:
コンピュータ・メディア : 単行資料
[NT 15000414] null:
616.3997
タイトル / 著者:
Dyslipidemias : pathophysiology, evaluation and management // edited by Abhimanyu Garg.
その他の著者:
出版された:
Totowa, NJ : : Humana Press :, 2015.
記述:
xvi, 525 p. : : ill., digital ;; 24 cm.
主題:
国際標準図書番号 (ISBN) :
9781607614241 (electronic bk.)
国際標準図書番号 (ISBN) :
9781607614234 (paper)
[NT 15000228] null:
Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
[NT 15000229] null:
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.?Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists.?For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field.?A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.# 0
Dyslipidemias[electronic resource] :pathophysiology, evaluation and management /
Dyslipidemias
pathophysiology, evaluation and management /[electronic resource] :edited by Abhimanyu Garg. - Totowa, NJ :Humana Press :2015. - xvi, 525 p. :ill., digital ;24 cm. - Contemporary endocrinology.
Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.?Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists.?For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field.?A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.# 0
ISBN: 9781607614241 (electronic bk.)
Standard No.: 10.1007/978-1-60761-424-1doiSubjects--Topical Terms:
353965
LC Class. No.: RC632.L5
Dewey Class. No.: 616.3997
Dyslipidemias[electronic resource] :pathophysiology, evaluation and management /
LDR
:03827nmm a2200289 a 4500
001
439016
003
DE-He213
005
20160107150140.0
006
m d
007
cr nn 008maaau
008
160315s2015 nju s 0 eng d
020
$a
9781607614241 (electronic bk.)
020
$a
9781607614234 (paper)
024
7
$a
10.1007/978-1-60761-424-1
$2
doi
035
$a
978-1-60761-424-1
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC632.L5
072
7
$a
MJG
$2
bicssc
072
7
$a
MED027000
$2
bisacsh
082
0 4
$a
616.3997
$2
23
090
$a
RC632.L5
$b
D998 2015
245
0 0
$a
Dyslipidemias
$h
[electronic resource] :
$b
pathophysiology, evaluation and management /
$c
edited by Abhimanyu Garg.
260
$a
Totowa, NJ :
$b
Humana Press :
$b
Imprint: Humana Press,
$c
2015.
300
$a
xvi, 525 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
Contemporary endocrinology
505
0
$a
Lipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents.
520
$a
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.?Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists.?For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field.?A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.# 0
650
a L
$2
lcstt.
$3
353965
700
a G
$3
383340
710
a S
$7
aProject Muse.
$3
540276
830
a C
$3
626084
~に基づいて 0 論評
論評
論評を追加
あなたの考えを共有してください。
Export
受取館
処理
...
パスワードを変更する
ログイン